行业发起的临床试验中出版权的限制。 - Suppr

Suppr

超能文献

Constraints on publication rights in industry-initiated clinical trials.

作者信息

Gøtzsche Peter C, Hróbjartsson Asbjørn, Johansen Helle Krogh, Haahr Mette T, Altman Douglas G, Chan An-Wen

出版信息

JAMA. 2006 Apr 12;295(14):1645-6. doi: 10.1001/jama.295.14.1645.

DOI:10.1001/jama.295.14.1645

PMID:16609085

Abstract

摘要

相似文献

Constraints on publication rights in industry-initiated clinical trials.行业发起的临床试验中出版权的限制。

JAMA. 2006 Apr 12;295(14):1645-6. doi: 10.1001/jama.295.14.1645.

[Constraints on publication rights in industry-initiated clinical trials--secondary publication].[行业发起的临床试验中出版权的限制——二次出版]

Ugeskr Laeger. 2006 Jun 19;168(25):2467-9.

Registering clinical trials in India.在印度注册临床试验。

Natl Med J India. 2006 Jan-Feb;19(1):1-3.

Sponsorship, authorship and accountability.赞助、作者身份与责任。

N Z Med J. 2001 Sep 14;114(1139):391-2.

[Ghostwriting].（代笔）

Tidsskr Nor Laegeforen. 2008 May 1;128(9):1039.

[Sponsorship, authorship and accountability].[赞助、作者身份与责任]

Tidsskr Nor Laegeforen. 2001 Sep 10;121(21):2531-2.

Sponsorship, authorship, and accountability.赞助、作者身份与责任。

Ugeskr Laeger. 2001 Sep 10;163(37):4983-5.

Sponsorship, authorship and accountability.赞助、作者身份与责任。

CMAJ. 2001 Sep 18;165(6):786-8.

Sponsorship, authorship and accountability.赞助、作者身份与责任。

N Z Med J. 2001 Dec 14;114(1145):559.

Sponsorship, authorship and accountability.赞助、作者身份与责任。

Lakartidningen. 2001 Oct 24;98(43):4694-6.

引用本文的文献

SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials.《SPIRIT 2025解释与阐述：随机试验方案更新指南》

BMJ. 2025 Apr 28;389:e081660. doi: 10.1136/bmj-2024-081660.

Are investigators' access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials.研究者是否有权获取试验数据和发表权受限，以及潜在的试验参与者是否了解这一点？试验方案和知情同意书的比较。

BMC Med Ethics. 2021 Aug 28;22(1):115. doi: 10.1186/s12910-021-00681-9.

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.评估钠-葡萄糖共转运蛋白 (SGLT)-2 抑制剂在 1 型糖尿病患者中导致酮症酸中毒的风险：一项荟萃分析和荟萃回归。

PLoS Med. 2020 Dec 29;17(12):e1003461. doi: 10.1371/journal.pmed.1003461. eCollection 2020 Dec.

Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects.重复横断面研究评估试验方案报告质量的原理与设计：遵循《渥太华小组声明》建议（ASPIRE）研究及相关项目

Trials. 2020 Oct 28;21(1):896. doi: 10.1186/s13063-020-04808-y.

Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study.随机临床试验中利益冲突的影响和管理：定性访谈研究。

BMJ. 2020 Oct 27;371:m3764. doi: 10.1136/bmj.m3764.

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.SGLT1/2 双重抑制剂索格列净在 1 型糖尿病中的疗效和安全性：随机对照试验的荟萃分析。

BMJ. 2019 Apr 9;365:l1328. doi: 10.1136/bmj.l1328.

Best practices in nutrition science to earn and keep the public's trust.营养科学领域赢得和保持公众信任的最佳实践。

Am J Clin Nutr. 2019 Jan 1;109(1):225-243. doi: 10.1093/ajcn/nqy337.

Did relaxing clinical trial regulation enhance the stock of scientific knowledge in India? Not necessarily.放松临床试验监管是否会增加印度的科学知识储备？不一定。

PLoS One. 2019 Jan 3;14(1):e0210163. doi: 10.1371/journal.pone.0210163. eCollection 2019.

Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors.学术机构与产业界在临床试验中的合作：对出版物的横断面研究和主要学术作者的调查。

BMJ. 2018 Oct 3;363:k3654. doi: 10.1136/bmj.k3654.

Freedom of Science - Can Industry Influence What Scientists Publish?科学的自由——产业界能影响科学家发表的内容吗？

Eur Endocrinol. 2014 Feb;10(1):10-13. doi: 10.17925/EE.2014.10.01.1. Epub 2014 Feb 28.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验